Otsuka Holdings Past Earnings Performance

Past criteria checks 1/6

Otsuka Holdings has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 10.5% per year. Otsuka Holdings's return on equity is 6.1%, and it has net margins of 6.7%.

Key information

1.4%

Earnings growth rate

1.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate10.5%
Return on equity6.1%
Net Margin6.7%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Otsuka Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:OS1 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,269,564151,575923,851312,313
30 Jun 242,179,961126,817888,794309,650
31 Mar 242,089,741137,563845,547312,223
31 Dec 232,018,568121,616807,355307,804
30 Sep 231,950,959184,702777,521297,102
30 Jun 231,871,228166,860757,007292,125
31 Mar 231,806,034172,194745,187283,851
31 Dec 221,737,998133,906724,129275,230
30 Sep 221,656,978109,845706,655263,543
30 Jun 221,593,768103,809678,679254,588
31 Mar 221,541,795104,036642,606243,043
31 Dec 211,498,276125,463622,326232,299
30 Sep 211,463,284147,019596,462221,303
30 Jun 211,446,198152,734579,099210,550
31 Mar 211,420,055155,109562,954211,122
31 Dec 201,422,826148,137562,434216,841
30 Sep 201,434,441143,398560,802219,909
30 Jun 201,420,552146,198558,797224,980
31 Mar 201,421,844145,709563,043219,069
31 Dec 191,396,240127,151557,607215,789
30 Sep 191,372,665116,333562,504211,273
30 Jun 191,344,78786,379567,319220,080
31 Mar 191,311,28778,918571,343224,569
31 Dec 181,291,98182,492564,374216,140
30 Sep 181,269,004117,106551,893212,434
30 Jun 181,262,916133,942544,768190,872
31 Mar 181,254,410114,206557,945181,513
31 Dec 171,239,952112,492558,677175,558
30 Sep 171,211,77275,029565,791185,597
30 Jun 171,196,15488,267557,511177,785
31 Mar 171,193,15994,933535,629169,451
31 Dec 161,195,54792,563535,852168,818
30 Sep 161,240,87471,521504,554164,309
30 Jun 161,294,17761,301532,243177,728
31 Mar 161,342,72868,735546,741192,335
31 Dec 151,445,22784,053597,350201,010
31 Dec 141,599,424151,237630,029255,907
30 Sep 141,541,631163,443602,577246,447
30 Jun 141,515,577156,499577,133247,685
31 Mar 141,452,759150,956542,805249,010
31 Dec 131,403,125174,046491,656241,922

Quality Earnings: OS1 has a large one-off loss of ¥236.9B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: OS1's current net profit margins (6.7%) are lower than last year (9.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OS1's earnings have grown by 1.4% per year over the past 5 years.

Accelerating Growth: OS1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: OS1 had negative earnings growth (-17.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).


Return on Equity

High ROE: OS1's Return on Equity (6.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies